Message Font: Serif | Sans-Serif
No. of Recommendations: 1
If this proves to work well, it could be huge a few years from now.

Exelixis Provides Update on Cabozantinib Development Activities
Timeline for reporting top-line data from EXAM extended by approximately three months Protocol for XL184-306 pivotal trial in CRPC submitted to FDA for review Management to hold conference call at 6:00 p.m. EDT/3:00 p.m. PDT today


Exelixis, Inc. (NASDAQ:EXEL) today announced an update to the timing for reporting top-line data from the ongoing phase 3 pivotal trial of cabozantinib in patients with medullary thyroid cancer (MTC), known as the EXAM trial. The company has extended the timing to report top-line data from this trial by approximately three months. The timeline is being extended from the middle of this year to provide additional time for the trial to reach the pre-specified number of progression-free survival (PFS) events required for un-blinding of the data.

Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.